Navigation Links
Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Maryland's Emerging Company of the Year Award
Date:5/19/2008

ROCKVILLE, Md., May 19 /PRNewswire-USNewswire/ -- On Thursday May 15, 2008 Sanaria Inc. was named Emerging Company of the Year at the annual Technology Council of Maryland's Tech Awards Celebration honoring the state's technology leaders and organizations.

http://techcouncilmd.com/News/tcmnews_080516.html

"All the members of the Sanaria team go to work every day with only one goal in mind, to develop a vaccine that will prevent millions of deaths from malaria," said Sanaria founder and CEO, Stephen L. Hoffman. "I am honored to accept this award on their behalf, and on behalf of our partners who have invested so much in us."

The PATH Malaria Vaccine Initiative, which is partnering with Sanaria Inc. to accelerate development of the company's novel malaria vaccine candidate, welcomed the news. "We at MVI are pleased at the recognition of our partner's efforts to establish a core platform technology for producing attenuated sporozoite malaria vaccines," said Director Dr. Christian Loucq.

The annual dinner and awards celebration was attended by Maryland Governor Martin O'Malley, additional state and local government representatives, and over 900 members of the Maryland technology and biotech industries.

About Sanaria Inc., The company's primary mission is to develop and commercialize a malaria sporozoite vaccine against Plasmodium falciparum, the parasite responsible for more than 95 percent of malaria-associated severe illness and death worldwide, and the malaria parasite for which there is the most significant drug resistance. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is http://www.sanaria.com.

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risks and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements relate to the use of funds to date to complete manufacturing the vaccine, and conduct initial clinical studies. Such risks and uncertainties include, but are not limited to, the Company's ability to raise funds on reasonable terms, the regulatory approval process, competitive products, and maintenance of its patent portfolio, among others.

Media contact: Adam Richman, Sanaria Inc., 9800 Medical Center Drive, Suite A209, Rockville, MD 20850 USA

Ph: +1-301-770-3222

Fax: +1-301-770-5554

Email: arichman@sanaria.com


'/>"/>
SOURCE Sanaria Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
2. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
3. UPDATE: Infant Primates Given Vaccines on U.S. Childrens Immunization Schedule Develop Behavioral Symptoms of Autism
4. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
5. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
6. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
7. Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains
8. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
9. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
10. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
11. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... that it will be participating in the Morgan Stanley ... Grand Hyatt hotel in New York.  Zimmer Biomet will ... Eastern Time. A live webcast of the ... website at http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... 2017  Medical professionals are expected to ... treating their patients. Medical simulations offer clinicians ... patients. Simulation provides a safe method for ... procedures, refine techniques and build confidence, without ... technology, such as augmented reality, will now ...
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
Breaking Medicine Technology:
(Date:9/25/2017)... Korea (PRWEB) , ... September 25, 2017 , ... Earlypicker ... looking for a one-stop shop for the hottest Korean cosmetics and fashion trends sweeping ... for a company that’s already well-known for the great offerings that allow Koreans everywhere ...
(Date:9/25/2017)... ... September 25, 2017 , ... “The Ministry of Reconciliation: A ... at the religious stand in the sensitive matter of sexual discrimination, and how ... of Reconciliation: A Compassionate and Realistic Approach to Evangelizing the LGBTQ Community” is ...
(Date:9/25/2017)... Conference (PRWEB) , ... September 25, 2017 , ... ... teamed up to deliver Netmail’s Hadron Data Auditing and eDiscovery services ... Netmail will be demo-ing their Hadron solution in a HIPAA/HITRUST Azure Cloud at the ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... **Presented by FDAnews**, Nov. 1-3, 2017 – Bethesda, MD, http://www.fdanews.com/fdainspectionssummit , ... colors. And then, on the tenth inspection it failed. , What went wrong? ...
(Date:9/24/2017)... ... September 25, 2017 , ... Bhowanie Benimadhu’s new book “ Our Creative ... of life and seeks answers in both Eastern and Western religious traditions and spirituality ... is in the mind of humankind for the past thousands of years and still ...
Breaking Medicine News(10 mins):